## 広島大学学位請求論文

# Mechanistic analysis of position-dependent fin regeneration in zebrafish (ゼブラフィッシュにおける位置特異的ヒレ再 生機構の解析)

## 2018年

広島大学大学院理学研究科

生物科学専攻

高山和也

## 目次

### 1. 主論文

Mechanistic analysis of position-dependent fin regeneration in zebrafish (ゼブラフィッシュにおける位置特異的ヒレ再生機構の解析)

髙山和也

- 2. 公表論文
- Leucine/glutamine and v-ATPase/lysosomal acidification via mTORC1 activation are required for position-dependent regeneration Kazuya Takayama, Akihiko Muto, Yutaka Kikuchi Scientific Reports, 2018;8(1):8278

## 主論文

## Mechanistic analysis of position-dependent fin regeneration in zebrafish

Kazuya Takayama

Department of Biological Science,

Graduate School of Science,

Hiroshima University

2018

### -Contents-

Chapter 1. General introduction	<b>5</b>
References	0
Chapter 2. Leucine/glutamine and v-ATPase/lysosomal acidification via mTORC1 activation ar	·e
required for position-dependent regeneration1	2
Abstract	3
Introduction	4
Results	6
DISCUSSION	1
Materials and Methods2	4
Acknowledgements	7
References	8
FIGURES	2
Supplementary figures	6
Chapter 3. General discussion	0
References	3
Acknowledgement	5

Chapter 1. General introduction

#### **General introduction**

Unlike mammals, some animals, like the adult teleost and urodele amphibians, can completely regenerate their appendages after amputation [1]. Although mice have a good capacity for organ regeneration, the ability to regenerate is limited [2]. In contrast, the teleost and urodele amphibians have this regenerative capacity throughout their lifespan. What is the difference between the mammal and some other animals that have a great capacity for organ regeneration? Understanding of this fascinating phenomenon more deeply may be beneficial in the medical field because the mechanism may be applicable to disease management and healing in the future.

As a potential model system for studying regeneration, the zebrafish has a lot of great advantages [3]. Firstly, they can regenerate organs relatively quickly throughout their lifespan, from the larvae stage to adulthood. Secondly, the sequence of their genome is known, so we can use the data set, forward genetic approaches, and some transgenics method. Finally, they can regenerate different kinds of organs such as the fin, brain, spinal cord, retina, and heart. Although each regeneration is induced each different system, but there are many common systems in same time.

The zebrafish has become the predominant model, because of these advantages. In most cases of fin regeneration research, we use the caudal fin because we can easily amputate it and observe the process of regeneration [4]. Zebrafish fins can be observed simply as being a construction of bone rays, which provide the fin shape and structure. Bone rays are composed of two sets of hemi-rays that are segmented into each bone. The fin ray bones are thought to be regenerated via direct ossification rather than cell differentiation from some premature cells, while other cells are structured in some tissues by fibroblasts, nerves, blood vessels, pigment, and mesenchymal tissues.

There are 3 steps in caudal fin regeneration [5][6][7]: wound healing, blastema formation, and regenerative outgrowth. Fin regeneration usually takes only 2 weeks to complete.

#### 1. Wound healing: 12 hours post amputation (hpa)

Following fin amputation, epidermal cells cover the amputation plane within an hour, while some cells migrate to the plane. At the same time, the cells migrate to below the amputation plane and start forming the premature cells, called the blastema.

#### 2. Blastema formation: 12-36 hpa

From 12 hpa to 36 hpa, changed premature cells, the blastema, begin to have a capacity for cell proliferation. The blastema is a highly proliferative mass of undifferentiated mesenchymal cells from which several cell types will differentiate in order to form the missing structures. This is derived from existing cells before amputation.

#### 3. Regenerative outgrowth: 36 hpa~

Regenerative outgrowth is induced by cell proliferation and dedifferentiation from the blastema. Gradually, the fin grows back its original shape, completing the regeneration around 14 days. Some of the blastema cells aligning the epithelial tissue start to differentiate into the scleroblasts, a process which depends on each signal arising from the apical epithelial cap (AEC). Within the following 3 to 14 days, the interactions between the AEC and the blastema assure the outgrowth of the regenerating fin and during this process, all cell types are redifferentiated and a new caudal fin is established. The cell mass has been proposed to play a critical role in the regulation of gene expression pattern and outgrowth throughout the fin regeneration due to the gene expressions of the many growth factors, which are implicated in important signaling pathways to induce the blastema cells, such as Wnt/b-Catenin Signaling, Fibroblast growth factors, Insulin-like growth factors, and Sonic hedgehog.

Recently, many researchers have tried to reveal the mechanism of regeneration, and they have reported new and important factors [8]. These include a lot of growth factors, immune system related factors, epigenetic modification related factors, and other factors involved in intercellular signaling pathways. However, a lot of details about the regeneration are still unknown and nobody can induce organ regeneration directly in the human body in the medical field.

One of the unsolved points in regeneration research is how the amputated fin regenerates until the original shape is completed. This phenomenon is thought to be induced by some critical factors. Many researchers, including me, believe this mechanism can be explained by the general concept of positional memory [9].

In the regeneration fin, the original appendages' size, shape, and some pattern is restored. The regeneration requires that spared cells sustain or recall the information encoding pattern. But almost all factors have not been implicated as a key factor of the position-dependent regeneration during appendage regeneration. Recent work has produced cellular and molecular models for blastema formation and regenerative

outgrowth during fin regeneration, but the mechanism of storing the original shape's information is still largely unknown. One paper about the mechanism has been reported in zebrafish fin regeneration [10]. During fin regeneration, the induction of cell proliferation mediated by Fgf signaling is different between the proximal and distal positions of the amputation plane. This induction starts at around 48 hpa and the late stage of regeneration follows this induction. Complete regeneration of the fin depends on the amputation position. However, nobody knows when this induction starts and what factor creates the difference.

In our laboratory, a previous has reported that the mechanistic target of rapamycin (mTORC1) signaling is the one of the earliest inducted signaling pathways after fin amputation [12] and I have found that the pathway is related to the position-dependent induction in the zebrafish fin regeneration. Additionally, I have discovered the signaling pathway is regulated by v-ATPase/lysosomal acidification during fin regeneration and the amino acid transporter is also required for this regeneration. In this chapter, I show the distribution of lysosome acidification mediated by amino acid transporter during fin regeneration. Finally, in chapter 3, I discuss how the new mechanism is involved in position-dependent zebrafish fin regeneration.



Figure. The process of fin regeneration

Following amputation, epidermal cells migrate to cover the injured plane and form the wound epidermis. The inter-ray cells de-differentiate and migrate to the under wound epidermis until 24 hpa. The de-differentiated cells begin to proliferate and form blastema. Formed blastema proliferate and re-differentiate, and regenerative outgrowth is induced. Finally, regeneration is completed for two weeks.

### References

- Gemberling, M., Bailey, T. J., Hyde, D. R. & Poss, K. D. The zebrafish as a model for complex tissue regeneration. *Trends in Genetics* 29, 611-620, doi:10.1016/j.tig.2013.07.003 (2013).
- 2 Gonzalez-Rosa, J. M., Burns, C. E. & Burns, C. G. Zebrafish heart regeneration: 15 years of discoveries. *Regeneration* **4**, 105-123, doi:10.1002/reg2.83 (2017).
- 3 Hirose, K., Shiomi, T., Hozumi, S. & Kikuchi, Y. Mechanistic target of rapamycin complex 1 signaling regulates cell proliferation, cell survival, and differentiation in regenerating zebrafish fins. *Bmc Developmental Biology* 14, doi:10.1186/s12861-014-0042-9 (2014).
- Lee, Y., Grill, S., Sanchez, A., Murphy-Ryan, M. & Poss, K. D. Fgf signaling instructs position-dependent growth rate during zebrafish fin regeneration. *Development* 132, 5173-5183, doi:10.1242/dev.02101 (2005).
- Monteiro, J. *et al.* V-ATPase Proton Pumping Activity Is Required for Adult
   Zebrafish Appendage Regeneration. *Plos One* 9,
   doi:10.1371/journal.pone.0092594 (2014).
- Nechiporuk, A. & Keating, M. T. A proliferation gradient between proximal and msxb-expressing distal blastema directs zebrafish fin regeneration. *Development* 129, 2607-2617 (2002).
- Pfefferli, C. & Jazwinska, A. The art of fin regeneration in zebrafish.
   *Regeneration* 2, 72-83, doi:10.1002/reg2.33 (2015).
- 8 Rabinowitz, J. S. *et al.* Transcriptomic, proteomic, and metabolomic landscape of positional memory in the caudal fin of zebrafish. *Proceedings of the National Academy of Sciences of the United States of America* **114**, E717-E726, doi:10.1073/pnas.1620755114 (2017).
- Sahara, M., Santoro, F. & Chien, K. R. Programming and reprogramming a human heart cell. *Embo Journal* 34, 710-738, doi:10.15252/embj.201490563 (2015).
- Sehring, I. M., Jahn, C. & Weidinger, G. Zebrafish fin and heart: what's special about regeneration? *Current Opinion in Genetics & Development* 40, 48-56, doi:10.1016/j.gde.2016.05.011 (2016).
- 11 Simoes, M. G. *et al.* Denervation impairs regeneration of amputated zebrafish fins. *Bmc Developmental Biology* **14**, doi:10.1186/s12861-014-0049-2 (2014).
- 12 Tanaka, E. M. & Reddien, P. W. The Cellular Basis for Animal Regeneration. Developmental Cell **21**, 172-185, doi:10.1016/j.devcel.2011.06.016 (2011).

13 Tzahor, E. & Poss, K. D. Cardiac regeneration strategies: Staying young at heart. *Science* **356**, 1035-1039, doi:10.1126/science.aam5894 (2017).

Chapter 2. Leucine/glutamine and v-ATPase/lysosomal acidification via mTORC1 activation are required for position-dependent regeneration.

#### Abstract

In animal regeneration, control of position-dependent cell proliferation is crucial for the complete restoration of patterned appendages in terms of both, shape and size. However, detailed mechanisms of this process are largely unknown. In this study, we identified leucine/glutamine and v-ATPase/lysosomal acidification, via mechanistic target of rapamycin complex 1 (mTORC1) activation, as effectors of amputation plane-dependent zebrafish caudal fin regeneration. mTORC1 activation, which functions in cell proliferation, was regulated by lysosomal acidification possibly via v-ATPase activity at 3 h post amputation (hpa). Inhibition of lysosomal acidification resulted in reduced growth factor-related gene expression and suppression of blastema formation at 24 and 48 hpa, respectively. Along the proximal-distal axis, position-dependent lysosomal acidification and mTORC1 activation were observed from 3 hpa. We also report that Slc7a5 (L-type amino acid transporter), whose gene expression is position-dependent, is necessary for mTORC1 activation upstream of lysosomal acidification during fin regeneration. Furthermore, treatment with leucine and glutamine, for both proximal and distal fin stumps, led to an up-regulation in cell proliferation via mTORC1 activation, indicating that leucine/glutamine signaling possesses the ability to change the position-Our findings reveal that leucine/glutamine and vdependent regeneration. ATPase/lysosomal acidification via mTORC1 activation are required for positiondependent zebrafish fin regeneration.

#### Introduction

Complete regeneration (in terms of both shape and size) of the patterned appendages is observed in some vertebrates such as fish and salamanders [1,2]. This restorative ability is achieved via cellular properties that control cell proliferation and patterning depending on regional-specific information, also known as positional memory [3-6]. To date, three factors (transmembrane receptor Prod1 [7,8], retinoic acid (RA) [5], and Hand2 [9]) have been proposed as effectors of the positional memory in salamander limbs, amphibian limbs, and zebrafish pectoral fins, respectively. The expression of Prod1 and hand2 exhibits a gradient along the proximal-distal (P-D) axis in salamander limbs 8 and zebrafish pectoral fins 9, respectively, while no gradient of the RA signaling components has been reported in salamander limbs or zebrafish fins prior to injury. Although a recent report identified many genes, proteins, and metabolites via omics analyses in addition to Prod1, RA, and Hand2 along the P-D axis of the zebrafish caudal fin 10, the detailed molecular regulatory mechanisms of position-dependent regeneration are still largely unknown.

Signaling molecules, such as transforming growth factor- $\beta$  (TGF- $\beta$ ), Wnt, fibroblast growth factor (FGF), Notch, Hedgehog, insulin-like growth factor (IGF), RA, and mechanistic target of rapamycin (mTOR) have been determined to be necessary for appendage regeneration [11,12]. Among them, the mTOR is well known to sense environmental cues (growth factors, nutrients, and the cellular energy change) and control the cell growth and metabolism [13]. mTOR belongs to a serine/threonine protein kinase family and exists as two distinct complexes-mTOR complex1 (mTORC1) and 2 (mTORC2) [13]. In the mTORC1 signaling pathway, growth factors, intracellular and environmental stresses (e.g. energy, oxygen, and DNA damage), and amino acids are known to be upstream regulators [14,15]. mTORC1 regulates cell growth via protein, lipid, and nucleotide synthesis, and it is also known to inhibit autophagy [14,15]. The amino acids, especially leucine, glutamine, and arginine, activate mTORC1 signaling via a lysosomal amino acid transporter (SLC38A9) and a RAS-related GTP-binding protein (Rag)/Regulator/vacuolar-type proton transporter H+-ATPase (v-ATPase) complex A previous report proved that the expression of v-ATPase demonstrated [14,15]. position-dependency and that the v-ATPase activity was necessary for the expression of aldehyde dehydrogenase 1 family, member A2 (aldh1a2) (a type of RA synthetase) during zebrafish caudal fin regeneration [16]. However, the function of the amino acids and SLC38A9/Rag/Regulator/v-ATPase complex in the position-dependent appendage regeneration process has not yet been reported.

Zebrafish caudal fins are complex appendages that are composed of epidermal cells, segmented bony rays, blood vessels, fibroblast-like mesenchymal cells, and nerve axons. Using zebrafish caudal fin regeneration systems, we have previously showed that mTORC1 signaling regulated cell proliferation, cell survival, and differentiation in zebrafish fin regeneration downstream of the IGF and Wnt pathways [17]. However, the regulation of mTORC1 activity via upstream regulators other than growth factors during fin regeneration has not yet been analyzed. In this study, we explored the upstream regulators of mTORC1 and identified the axis of leucine/glutamine signaling-v-ATPase/lysosomal acidification via mTORC1 activation as an effector of position-dependent zebrafish caudal fin regeneration.

#### Results

# mTORC1 activation is not controlled by IGF and Wnt signaling at 3 h post amputation

We have previously reported that mTORC1 activation was regulated by both IGF and Wnt signaling pathways at 24 and 48 h post amputation (hpa) during zebrafish fin regeneration by using pharmacological inhibitors, NVP-ADW742 (an IGF-1R inhibitor) and IWP-2 (a Wnt/β-catenin inhibitor) [17]. However, amino acids and environmental stresses have been known to function as the upstream regulators of mTORC1 in addition to growth factors [14,15]. To explore the involvement of the upstream regulators other than growth factors in mTORC1 regulation, we carefully observed the expression of phosphorylated S6 kinase (p-S6K; activated form of S6K), a downstream target of mTORC1, during fin regeneration while IGF or Wnt signaling was inhibited. The p-S6K fluorescence intensities per area that consist of the whole regenerates and 500 µm below the amputation plane were significantly reduced via rapamaycin (rapa) treatment (Fig. 1C-D', G, H-I', L, M-N', and Q). On the other hand, the p-S6K fluorescence intensities in IGF or Wnt signaling inhibited-fin stumps remained unchanged at 3 hpa (Fig. 1C, C', and E-G), but were significantly reduced at 6 and 12 hpa when compared to those in the DMSO-treated fin stumps (Fig. 1H, H', J-L, M, M', and O-Q). The results of p-S6K fluorescence intensities at 3 and 12 hpa observed by immunohistochemical staining were further supported by western blotting analysis (Fig. S1), indicating that mTORC1 activation is not under the control of IGF and Wnt signaling at 3 hpa during fin regeneration.

# Lysosomal acidification, possibly through v-ATPase, is required for mTORC1 activation

Previous studies using cell culture systems reported that the mTORC1 activation was closely linked to the SLC38A9/Rag/Regulator/v-ATPase complex on the lysosomal surface [13-15]. Interestingly, one of components in the lysosomal protein complex, v-ATPase, is required for zebrafish fin regeneration [16]. Therefore, we first examined the activity of the proton transporter, v-ATPase, during fin regeneration with the help of the LysoTracker, which is a fluorescent dye for labelling acidic lysosomes. High fluorescent signals of the LysoTracker were observed at 3 hpa at the amputation plane, which gradually decreased until 12 hpa (Fig. S2), showing the acidification of lysosomes during fin regeneration. To examine the relationship between the activation of v-ATPase and mTORC1, we further examined the functional inhibition of v-ATPase by using two

different pharmacological inhibitors, Concanamycin A (ConcA) [18] and Bafilomycin A1 (BafA1) [19]. We found that the p-S6K fluorescence intensity and p-S6K protein level were significantly reduced in each inhibitor-treated fin stump at 3 hpa by immunohistochemistry and western blotting, respectively (Fig. 2B-F). Lysosomal acidification at the amputation plane was suppressed by ConcA or BafA1 treatment at 3 hpa (Fig. 2G-J), suggesting that one of the mTORC1 regulators is a v-ATPase that regulates lysosomal acidification at this regeneration stage.

To evaluate the lysosomal acidification on mTORC1 activation, we next examined the inhibition of lysosomal acidification via treatment of ammonium chloride (NH<sub>4</sub>Cl) or chloroquine (CQ), both of which are the weak bases and function to increase the lysosomal pH [20]. The reagent treatment lead to a significant reduction of the p-S6K fluorescence intensity and p-S6K protein level at 3 hpa by immunohistochemistry and western blotting, respectively (Fig. 3B-F). We confirmed that lysosomal acidification was blocked in NH<sub>4</sub>Cl- or CQ-treated fin stumps at 3 hpa using LysoTracker (Fig. S3) and apoptosis was not increased by the reagent treatment at 3 and 24 hpa (Fig, S4). The expression of growth factor-related genes (wnt10a, igf2b, aldh1a2, and fgf20a) [11,12] was significantly downregulated at 24 hpa in NH<sub>4</sub>Cl- or CQ-treated fin stumps (Fig. 3G). To further investigate the relationship between p-S6K and lysosomal acidification, we double stained fin stumps using the LysoTracker and p-S6K antibody. Approximately 55 % of the p-S6K-positive cells were LysoTracker-positive in the fin stumps at 3 hpa (Fig. 3H-K), suggesting an association between mTORC1 activation and lysosomal acidification. Collectively, these results showed that lysosomal acidification is required to activate mTORC1 possibly via v-ATPase activity.

# Lysosomal acidification and mTORC1 activation are dependent on the amputation plane along the P-D axis

A previous report showed that the expression of *atp6v1e1b*, a v-ATPase family gene, and the H+ efflux in the proximal regenerates were higher than those in the distal regenerates at 12 hpa [16]. These results prompted us to analyze whether the acidification of lysosome was dependent on the position of the amputation plane along the P-D axis. LysoTracker fluorescence was detected at both proximal and distal amputation planes from 1 hpa (Fig. 4B-E"). The fluorescence intensities at the proximal regions were significantly higher than those at the distal regions, and this difference in fluorescence intensities remained until 6 hpa (Fig. 4F). Cryosections under the confocal microscope showed that the fluorescent LysoTracker-positive cells were observed in the epidermis and fin rays of proximal and distal fin stumps at 3 hpa (Fig. 4G and H).

Moreover, the ratio of the fluorescent LysoTracker-positive cell number/total cell number (RLT) within the area that consist of the whole regenerates and 500 µm below the amputation plane in proximal stumps was significantly higher than that in distal stumps at 3 hpa (Fig. 4I). Because lysosomal acidification is required for mTORC1 activation, the position-dependence of p-S6K- and proliferating cell nuclear antigen (PCNA, a maker for proliferative cells [21])-positive cells was also examined during fin regeneration. We found that p-S6K fluorescence intensity and p-S6K protein level in the proximal regions were significantly higher than those in the distal regions during fin regeneration at 3 and 12 hpa by immunohistochemistry and western blotting, respectively (Fig. 5A-F). Consistent with previous results that reported the regulation of cell proliferation via mTORC1 [17], the ratios of PCNA-positive cell number/total cell number (RPTs) within the area that consist of the whole regenerates also showed dependence on the amputation plane at 36 and 48 hpa (Fig. 5G-K). Our results suggest that position-dependent lysosomal acidification may cause the differences in mTORC1 activation between the proximal and distal amputation planes.

#### L-type amino acid transporter 1 is required for mTORC1 activation

Previous studies implicated branched-chain amino acids, especially leucine, and their Ltype amino acid transporters (LATs) as effective activators of mTORC1 [22-25]. Because there are five LATs (LAT1; Slc7a5, LAT2; Slc7a8a and Slc7a8b, LAT3; Slc43a1a and Slc43a1b) in zebrafish as per the zebrafish database, we first examined the expression of these LATs at 0, 1, 3, 6, and 12 hpa. Among them, slc7a5 showed the highest increase in expression levels at 3 hpa, and its expression in the proximal region was significantly higher than that in the distal region (Fig. 6A and Fig. S5). Therefore, we further performed vivo-morpholino oligo nucleotide (MO)-mediated slc7a5 knockdown experiments during fin regeneration. We first confirmed that a previously reported slc7a5-MO [26] blocked the exon1 splicing of slc7a5 pre-mRNA detected via quantitative real-time PCR (qPCR) (Fig. S6). Formation of blastema, a heterogeneous population of progenitor cells, was suppressed in *slc7a5*-MO-injected fin regenerates when compared to in standard MO (st-MO)-injected fin regenerates at 48 hpa (Fig. 6C-Consistent with the suppressed blastema formation, p-S6K fluorescence intensity, **F**). p-S6K protein level, and expression of growth factor-related genes were significantly reduced in slc7a5-MO-injected fins (Fig. 6G-K). We further found via LysoTracker analysis that lysosomal acidification was significantly reduced in *slc7a5*-MO-injected fin stumps when compared to in st-MO-injected fin stumps (Fig. 6L-N). In addition to knockdown experiments, we have used a Slc7a5-specific inhibitor, JPH203 [27], to block

the cellular entry of amino acids. Similar to vivo-MO mediated knockdown experiments, blastema formation at 48 hpa, the p-S6K fluorescence intensity, p-S6K protein level, and lysosomal acidification by LysoTracker were significantly reduced at 3 hpa in JPH203-treated fin stumps when compared to those in DMSO-treated fins (Fig. S7). These our findings suggest that amino acid signaling through the Slc7a5 transporter is involved in mTORC1 activation possibly via lysosomal acidification during fin regeneration.

# Treatment with leucine and glutamine increases mTORC1 signaling and cell proliferation in both proximal and distal fin stumps

A recent study showed that mTORC1 signaling stimulated by leucine and glutamine rescues defects associated with Roberts Syndrome in zebrafish [28]. Based on this finding, we wondered if the amino acids, leucine and glutamine, were involved in mTORC1 activation during fin regeneration. To explore this possibility, we carried out leucine and/or glutamine treatment in fin-amputated fish. Fin stumps after leucine or glutamine treatment showed no increased mTORC1 activation (Fig. S8), whereas cotreatment with leucine and glutamine (LG) significantly increased the p-S6K fluorescence intensity at 3, 6, 12 hpa and p-S6K protein level at 3 hpa in both proximal and distal fin stumps (Fig. 7B-G). In addition, although LysoTracker fluorescence intensities were not increased by leucine or glutamine treatment (Fig. S9B-K), they showed an LG concentration-dependent increase in LG-treated fin stumps compared to control fin stumps at 3 hpa (Fig. S9L-P). Consistent with increase of the p-S6K fluorescence intensities, RPTs in both proximal and distal regenerates were increased in LG-treated fin regenerates at 36 hpa (Fig. 7H-L). We further found that LG treatment significantly increased the expression of growth factor-related genes, except wnt10a, at 24 hpa (Fig. 7M). These results showed that LG signaling had the ability to change positiondependent cell proliferation via mTORC1 activation during fin regeneration. Because it is known that amino acid signaling is one of upstream regulators of mTORC1 via the SLC38A9/Rag/Regulator/v-ATPase complex [13-15], we further tested the hierarchical relationship between LG signaling and v-ATPase/lysosomal acidification. The p-S6K fluorescence intensity and p-S6K protein level were significantly increased by LG treatments at 3 hpa; however, this increased level of mTORC1 signaling was suppressed by the co-treatment with ConcA or NH4Cl (Fig. 7N-T). Furthermore, up-regulation of LysoTracker fluorescence intensity by LG treatment was annulled by slc7a5-MO injection (Fig. S10). Results of the LG signal activation experiments, combined with the slc7a5 knockdown data, suggest that LG and their transporter, Slc7a5, are upstream

regulators of mTORC1 activity via v-ATPase/lysosomal acidification.

#### DISCUSSION

One of the most important processes in regeneration is the complete restoration of lost tissues or organs by cellular factors that regulate position-dependent cell proliferation and patterning (positional memory). Because the mTORC1 signaling pathway plays a central role in cell proliferation via the production of proteins, lipids, and nucleotides, and suppression of catabolic pathways such as autophagy, it is a potent candidate effector of position-dependent regeneration. In this study, we arrived at four conclusions. First, lysosomal acidification, possibly through v-ATPase activity, is required for mTORC1 Second, both lysosomal acidification and mTORC1 activation are dependent activation. on the amputation plane along the P-D axis. Third, an amino acid transporter Slc7a5 is necessary for mTORC1 activation and the expression of growth factor-related genes. Fourth, leucine and glutamine, which functions upstream of v-ATPase/lysosomal acidification, have the ability to increase cell proliferation via mTORC1 activation in both Based on our results, we propose a molecular proximal and distal fin regenerates. pathway that leads to the position-dependent cell proliferation during zebrafish caudal fin regeneration (Fig. S11). Leucine and glutamine are proximally enriched in unamputated Leucine/glutamine signaling via Slc7a5 initiates vfins as shown previously [10]. ATPase activity in a position-dependent manner and causes lysosomal acidification. The position-dependent v-ATPase activity/lysosomal acidification activates the mTORC1 signaling, which leads to cell proliferation and upregulation of growth factor-related gene expression directly or indirectly.

In addition to leucine/glutamine, mTORC1 senses and responds to various stresses, such as energetic/metabolic stress and oxidative stress, but most of these stresses are repressive [29]. In contrast, a previous report using a cell culture system revealed that oxidative stress activates mTORC1 through modulating the TSC1/TSC2-Rheb GTPase pathway [30]. Oxidative stress is one of main regulation factors for zebrafish cauda fin regeneration: reactive oxygen species (ROS), such as H<sub>2</sub>O<sub>2</sub>, production was gradually increased at the amputation plane by 16 hpa [31], and nerves and H<sub>2</sub>O<sub>2</sub> levels controlled each other in a positive feedback loop [32]. Moreover, the spatial and temporal localization of ROS is closely similar to that of lysosome acidification. These previous data, combined with our results, suggest that oxidative stress might be one of upstream regulators for mTORC1 activation.

Double staining experiments with p-S6K and LysoTracker showed that approximately 55 % of p-S6K-positive cells were fluorescent LysoTracker-negative at 3 hpa (Fig. 3H-K). A possible explanation for this result is that lysosomal acidification probably

occurred before 3 hpa and therefore, LysoTracker fluorescence had already disappeared at 3 hpa. Another possibility is that upstream environmental signals of mTORC1 other than amino acids and growth factors, such as oxygen and energy, activate mTORC1 within 3 hpa. It would be pertinent to explore these upstream environmental signals that function in mTORC1 activation immediately after fin-amputation.

Recently, three amino acids (leucine, glutamine, and arginine) were implicated in the activation of mTORC1 through various amino acid sensing mechanisms [15,25,33]. Some amino acid sensing mechanisms for mTORC1 activation have been reported: binding of cytosolic leucine and Sestrin2, or cytosolic arginine and Cellular Arginine Sensor for mTORC1 (CASTOR1), prevents Sestrin2-GAP activity towards Rags2 (GATOR2), or CASTOR1-GATOR2 interaction via GATOR1 inactivation, leading to increased Rag-dependent mTORC1 signaling, respectively [15,25,33]; glutamine and leucine activate mTORC1 via glutaminolysis and  $\alpha$ -ketoglutarate production upstream of Rag [34]; mTORC1 is activated by glutamine via adenosine diphosphate ribosylation factor-1 dependent on v-ATPase [35]. In this study, we showed that individual leucine or glutamine treatments had no effect on mTORC1 activation during fin regeneration, whereas treatment of both leucine and glutamine activated mTORC1 signaling. There are two possible explanations for this result; one is that both amino acids are required for mTORC1 activation as in the glutaminolysis and  $\alpha$ -ketoglutarate production pathway, as mentioned above; while the other possibility is that, because Lat1 (Slc7a5) and 4F2hc (Slc3a2) are bi-directional transporters 36, leucine is transported into the cytosol instead of the glutamine efflux. A recent study revealed that Lat1/4F2hc is recruited by lysosomal-associated transmembrane protein 4b (LAPTM4b) to the lysosome [37]. This recruitment leads to uptake of leucine into the lysosome and is required for mTORC1 activation depending on v-ATPase activity. These previous results are consistent with our results that show the axis of leucine/glutamine signaling-v-ATPase/lysosomal acidification is associated with mTORC1 activation. Further studies are needed to elucidate how leucine and glutamine activate mTORC1 during fin regeneration.

Previous reports revealed that the  $H^+$  pump v-ATPase activity is necessary for regeneration of *Xenopus* larval tail [38] and zebrafish caudal fin [16]. In Xenopus larvae, v-ATPase mRNA and protein are expressed in the regeneration bud, and its protein is localized in the cell-membrane of the bud cells [38]. The v-ATPase activity changes membrane voltage in the bud cells via the  $H^+$  efflux and repolarization by its activity is necessary for tail outgrowth [38]. Like the *Xenopus* larval tail,  $H^+$  efflux via v-ATPase is required for blastema cell proliferation in zebrafish caudal fin regeneration at 24 and 48 hpa [16]. In addition to the previous study results, we also found that lysosomal

acidification, possibly through v-ATPase, is required for activation of mTORC1 signaling within 3 hpa. To date, only one study reported that lysosomal pH functions not only in mTORC1 activation, but also in its deactivation via protein degradation in osteoclasts [39]. It is possible that lysosomal pH itself may affect the amino acid transportation into the lysosome, amino acid sensing in the lysosome, or formation of the Rag/Regulator/v-ATPase complex formation on the lysosome membrane. Our results combined with previous data showed that v-ATPase has dual functions in both lysosomal pH control and plasma membrane voltage for zebrafish caudal fin regeneration at different regeneration stages.

However, the most important finding of this study is that leucine/glutamine and v-ATPase/lysosomal acidification via mTORC1 activation are required for the positiondependent fin regeneration. A recent report showed by metabolomic analyses that many specific amino acids are proximally or distally enriched in uninjured zebrafish caudal fin along the P-D axis. Both leucine and glutamine were identified as proximally-enriched amino acids [10]. In addition, the expression of *atp6v1e1b*, a component of the v-ATPase complex, in the proximal regenerates was higher than that in the distal regenerates [16]. In this study, we also showed that the expression of *slc7a5*, encoding L-type amino acid transporter, in the proximal regenerates was higher than that in the distal regenerates at 3 hpa, and that treatment with leucine and glutamine lead to the upregulation of PCNA expression in the distal regenerates at 36 hpa. Furthermore, inhibition of leucine/glutamine signaling and lysosomal acidification resulted in downregulation of growth factor gene expression, such as wnt10a, igf2b, aldh1a2, and fgf20a. Cumulatively, these results suggest that the axis of leucine/glutamine signaling-v-ATPase/lysosomal acidification via mTORC1 activation is a potent candidate effector of the position-dependent regeneration along the P-D axis at the early stage of fin regeneration (within 3 hpa). Moreover, differences in cell proliferation along the P-D axis are regulated by mTORC1 or possibly by growth factors downstream of this axis.

#### **Materials and Methods**

# Zebrafish husbandry, drug treatments, LysoTracker staining, amino acid treatments, and morpholino knockdown

All zebrafish experiments were conducted in strict accordance with relevant nation and international guidelines: 'Act on Welfare and Management of Animals' (Ministry of Environment of Japan), and were approved by the Hiroshima University Animal Research Committee (Permit Number: F17-2). For caudal fin amputation, adult zebrafish (AB/Tüebingen strain) were anesthetize using Tricaine (Sigma-Aldrich) and the caudal fins were amputated with razor blades along the dorsoventral axis. The proximal or distal amputations were performed as described previously [16]; for distal amputation, one or two ray segments were cut before the first ray bifurcation, and for proximal amputation, two segments distal to the most posterior scale covering the fin base were cut. In case amputation position is not specified, caudal fins were amputated at the proximal position.

Rapamycin (2.4  $\mu$ M, LC Laboratories), NVP-ADW742 (5  $\mu$ M, AdooQ Biosciences), IWP-2 (10  $\mu$ M, Promega), CQ (4.5 mM, Sigma-Aldrich), NH<sub>4</sub>Cl (5 mM, Sigma-Aldrich), and JPH203 (40  $\mu$ M, Chemescene) were used as specific inhibitors. All inhibitors, except CQ and NH<sub>4</sub>Cl, were dissolved in DMSO, with a 0.1% final DMSO concentration in fish water. The control fish were maintained in fish water (for CQ and NH<sub>4</sub>Cl) or with 0.1% DMSO (for rapamycin, NVP-ADW742, IWP-2, and JPH203) at 28.5 °C and this water containing respective drug was replaced daily. These treatments started 12 h before fin amputation. Two fish were placed in 50 ml of fish water containing respective drug and during the drug treatment, the fish were fed once a day. ConcA (200 nM, Santa Cruz Biotechnology) or BafA1 (200 nM, Cell Signaling) were dissolved in 100 % DMSO and diluted in Danieau medium 16. This diluted solution was injected into amputated fins at 1 hpa.

For LysoTracker staining, fin-amputated adult fish were incubated in LysoTracker Red DND-99 (ThermoFisher Scientific) solution diluted in fish water (1:1000) at 28.5 °C for 15 min before live imaging. To observe longitudinal ray sections, 2 nl of the diluted LysoTracker solution (1  $\mu$ M) was injected directly into the 2nd, 3rd, and 4th fin rays from the dorsal and ventral amputated fins below the amputation plane. For leucine and glutamine treatment, the fish were incubated in the fish water containing 5, 15, and 25 mM L-leucine (Sigma-Aldrich) and/or L-glutamine (Sigma-Aldrich). The fish water containing of the two amino acids was replaced every 12 h.

For MO knockdown experiments, we used vivo-MO targeted against slc7a5 and

standard control vivo-MO (st-MO) (GeneTools, LLC) as following: *slc7a5* vivo-MO (slc7a5-MO) 5'-AGGTAACAGTTTACTTACGTATACA-3' [26], st-MO 5'-CCTCTTACCTCAGTTACAATTTTATA-3'. *slc7a5*-MO (1 mM) or st-MO (1 mM) was injected into each inter-ray 3 h before fin amputation, and then every 12 h before observation or harvest, as described previously [40].

#### Immunohistochemical staining and detection of cell death

The amputated fins were fixed overnight in 4% paraformaldehyde in 0.1 M phosphatebuffered saline at 4 °C, embedded in Tissue-Tek O.C.T compound (Sakura Finetek), and cryosectioned to 14 µm thickness by using a Leica CM3050S [17]. The following primary antibodies were used: anti-PCNA mouse monoclonal antibody at 1:1000 (Sigma, #P8825) and phospho-S6 ribosomal protein (Ser240/244) rabbit polyclonal antibody at 1:300 (Cell Signaling, #2215). The following secondary antibodies were used: Alexa Fluor<sup>®</sup> 488 goat anti-rabbit IgG antibody at 1:500 (Invitrogen, Life Technologies Corp.) and Alexa Fluor<sup>®</sup> 594 goat anti-mouse IgG antibody at 1:500 (Invitrogen, Life Technologies Corp.). 4',6-diamidino-2-phenylindole (DAPI) was used for nuclei staining at a concentration of 1:1000. To detection apoptotic cells, we performed TUNEL staining using an In situ cell death detection kit (Roche, #11684795910) according to the manufacturer's instructions. The images were captured using an Olympus FV1000-D confocal microscope with the same exposure times using the FluoView software. Eight optical sections per one cryosection along the z-axis were taken in 0.67 µm intervals, and the captured images were analyzed using ImageJ (NIH).

#### qPCR analyses

Extraction of total RNA from regenerating fins was performed as described previously 41. Five independent qPCR experiments of ten genes (*wnt10a, igf2b, aldh1a2, fgf20a, slc7a5, slc7a8a, slc7a8b, slc43a1a, slc43a1b,* and *ribosomal protein L13a (rpl13a)*) for gene expression and MO efficacy was performed in duplicates using the Thermal Cycler Dice Real-Time System II and SYBR Premix Ex Taq II (TAKARA) as described previously [42]. Zebrafish *rpl13a* was used as a reference gene. The qPCR primers are listed in Table S1.

#### LysoTracker image analyses

Fluorescent LysoTracker images were acquired using a Leica MZ FLIII microscope and Penguin 600CL cooled CCD camera (Pixera). As described previously [43], average LysoTracker fluorescence intensity was measured using the ImageJ software (NIH) with the following formula: [integrated intensity in the whole amputation plane area (W 500  $\mu$ m × L full-length of the amputation plane) – mean fluorescence intensity of background].

#### Western blotting

Western blotting was performed as described previously [44]. Fins were lysed in  $2 \times$ SDS-sample buffer (125mM Tris-HCl (pH 6.8), 4% SDS, 20% Glycerol, 0.01% bromophenol blue, 2% 2-mercaptoethanol) containing a protease inhibitor cocktail (Roche, #11836153001) and a phosphatase inhibitor cocktail (Nacalai, #07574-61). Total proteins (5  $\mu$ g) were separated by SDS-PAGE and transferred to a polyvinylidene fluoride (PVDF) membrane. The PVDF membranes were incubated overnight with primary antibodies: anti-yTubulin (Sigma-Aldrich, #T6557) at 1:20000, ribosomal protein S6 Antibody (C-8) (Santa Cruz Biotechnology, #sc-74459) at 1:1000, and antiphospho-S6 ribosomal protein (Ser240/244) (Cell signaling, #2215) at 1:1000. For detection, horseradish peroxidase-coupled secondary antibodies: goat anti-mouse IgG-HRP at 1:10000 (Santa Cruz Biotechnology, #sc-2055) and mouse anti-rabbit IgG-HRP at 1:10000 (Santa Cruz Biotechnology, #sc-2357), and the ECL Prime Western Blotting Detection Reagent (GE Healthcare, #RPN2232) were used, according to the manufacturer's instructions. A densitometric analysis of the western blotting was performed using ImageJ, with yTubulin for normalization.

#### Statistical analyses

All experiments were performed independently more than three times and the results were reported as means  $\pm$  Standard Error of Mean (SEM). More than 100 cells for distal amputation and 500 cells for proximal amputation were used for quantification of fluorescence intensity (for p-S6K and LysoTracker) or quantification of RLT, RPT, and percentage of TUNEL+ cells. Statistical significance was determined by using the Student's t-test. *p* values of  $\leq 0.05$  were considered to be statistically significant.

### Acknowledgements

We thank Institute for Amphibian Biology in Hiroshima University for cryostat sectioning and qPCR; the members of Kikuchi and Atsushi Suzuki laboratories in Hiroshima University for helpful discussion and critical comments. This study was supported by grants from Grant-in-Aid for Scientific Research from the JSPS (KAKENHI JP15J05983) to K.T.

#### References

[1] Poss, K. D. Advances in understanding tissue regenerative capacity and mechanisms in animals. Nat Rev Genet 11, 710-722, doi:10.1038/nrg2879 (2010).

[2] Tanaka, E. M. & Reddien, P. W. The cellular basis for animal regeneration. Dev Cell 21, 172-185, doi:10.1016/j.devcel.2011.06.016 (2011).

[3] Lee, Y., Grill, S., Sanchez, A., Murphy-Ryan, M. & Poss, K. D. Fgf signaling instructs position-dependent growth rate during zebrafish fin regeneration. Development 132, 5173-5183, doi:10.1242/dev.02101 (2005).

[4] Brockes, J. P. & Kumar, A. Appendage regeneration in adult vertebrates and implications for regenerative medicine. Science 310, 1919-1923, doi:10.1126/science.1115200 (2005).

[5] Stocum, D. L. & Cameron, J. A. Looking proximally and distally: 100 years of limb regeneration and beyond. Dev Dyn 240, 943-968, doi:10.1002/dvdy.22553 (2011).

[6] Tornini, V. A. & Poss, K. D. Keeping at arm's length during regeneration. Dev Cell 29, 139-145, doi:10.1016/j.devcel.2014.04.007 (2014).

[7] da Silva, S. M., Gates, P. B. & Brockes, J. P. The newt ortholog of CD59 is implicated in proximodistal identity during amphibian limb regeneration. Dev Cell 3, 547-555 (2002).

[8] Kumar, A., Gates, P. B. & Brockes, J. P. Positional identity of adult stem cells in salamander limb regeneration. C R Biol 330, 485-490, doi:10.1016/j.crvi.2007.01.006 (2007).

[9] Nachtrab, G., Kikuchi, K., Tornini, V. A. & Poss, K. D. Transcriptional components of anteroposterior positional information during zebrafish fin regeneration. Development 140, 3754-3764, doi:10.1242/dev.098798 (2013).

[10] Rabinowitz, J. S. et al. Transcriptomic, proteomic, and metabolomic landscape of positional memory in the caudal fin of zebrafish. Proc Natl Acad Sci U S A 114, E717-E726, doi:10.1073/pnas.1620755114 (2017).

[11] Gemberling, M., Bailey, T. J., Hyde, D. R. & Poss, K. D. The zebrafish as a model for complex tissue regeneration. Trends Genet 29, 611-620, doi:10.1016/j.tig.2013.07.003 (2013).

[12 Wehner, D. & Weidinger, G. Signaling networks organizing regenerative growth of the zebrafish fin. Trends Genet 31, 336-343, doi:10.1016/j.tig.2015.03.012 (2015).

[13] Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274-293, doi:10.1016/j.cell.2012.03.017 (2012).

[14] Shimobayashi, M. & Hall, M. N. Making new contacts: the mTOR network in

metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 15, 155-162, doi:10.1038/nrm3757 (2014).

[15] Saxton, R. A. & Sabatini, D. M. mTOR Signaling in Growth, Metabolism, and Disease. Cell 169, 361-371, doi:10.1016/j.cell.2017.03.035 (2017).

[16] Monteiro, J. et al. V-ATPase proton pumping activity is required for adult zebrafish appendage regeneration. PLoS One 9, e92594, doi:10.1371/journal.pone.0092594 (2014).
[17] Hirose, K., Shiomi, T., Hozumi, S. & Kikuchi, Y. Mechanistic target of rapamycin complex 1 signaling regulates cell proliferation, cell survival, and differentiation in regenerating zebrafish fins. BMC Dev Biol 14, 42, doi:10.1186/s12861-014-0042-9 (2014).

[18] Huss, M. et al. Concanamycin A, the specific inhibitor of V-ATPases, binds to the V(o) subunit c. J Biol Chem 277, 40544-40548, doi:10.1074/jbc.M207345200 (2002).

[19] Gagliardi, S., Rees, M. & Farina, C. Chemistry and structure activity relationships of bafilomycin A1, a potent and selective inhibitor of the vacuolar H+-ATPase. Curr Med Chem 6, 1197-1212 (1999).

[20] Ohkuma, S. & Poole, B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A 75, 3327-3331 (1978).

[21] Woods, A. L. et al. The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology 19, 21-27 (1991).

[22] Stipanuk, M. H. Leucine and protein synthesis: mTOR and beyond. Nutr Rev 65, 122-129 (2007).

[23] Wang, Q. & Holst, J. L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia. Am J Cancer Res 5, 1281-1294 (2015).

[24] Goberdhan, D. C., Wilson, C. & Harris, A. L. Amino Acid Sensing by mTORC1: Intracellular Transporters Mark the Spot. Cell Metab 23, 580-589, doi:10.1016/j.cmet.2016.03.013 (2016).

[25] Zheng, L. et al. Recent Advances in Understanding Amino Acid Sensing Mechanisms that Regulate mTORC1. Int J Mol Sci 17, doi:10.3390/ijms17101636 (2016).
[26] Chung, J. et al. The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability. Sci Signal 8, ra34, doi:10.1126/scisignal.aaa5903 (2015).

[27] Oda, K. et al. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci 101, 173-179, doi:10.1111/j.1349-7006.2009.01386.x (2010).

[28] Xu, B., Lee, K. K., Zhang, L. & Gerton, J. L. Stimulation of mTORC1 with L-leucine

rescues defects associated with Roberts syndrome. PLoS Genet 9, e1003857, doi:10.1371/journal.pgen.1003857 (2013).

[29] Su, K. H. & Dai, C. mTORC1 senses stresses: Coupling stress to proteostasis. Bioessays 39, doi:10.1002/bies.201600268 (2017).

[30] Yoshida, S. et al. Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway. J Biol Chem 286, 32651-32660, doi:10.1074/jbc.M111.238014 (2011).

[31] Gauron, C. et al. Sustained production of ROS triggers compensatory proliferation and is required for regeneration to proceed. Sci Rep 3, 2084, doi:10.1038/srep02084 (2013).

[32] Meda, F. et al. Nerves Control Redox Levels in Mature Tissues Through Schwann Cells and Hedgehog Signaling. Antioxid Redox Signal 24, 299-311, doi:10.1089/ars.2015.6380 (2016).

[33] Carroll, B. & Dunlop, E. A. The lysosome: a crucial hub for AMPK and mTORC1 signalling. Biochem J 474, 1453-1466, doi:10.1042/BCJ20160780 (2017).

[34] Durán, R. V. et al. Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell 47, 349-358, doi:10.1016/j.molcel.2012.05.043 (2012).

[35] Jewell, J. L. et al. Metabolism. Differential regulation of mTORC1 by leucine and glutamine. Science 347, 194-198, doi:10.1126/science.1259472 (2015).

[36] Nicklin, P. et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136, 521-534, doi:10.1016/j.cell.2008.11.044 (2009).

[37] Milkereit, R. et al. LAPTM4b recruits the LAT1-4F2hc Leu transporter to lysosomes and promotes mTORC1 activation. Nat Commun 6, 7250, doi:10.1038/ncomms8250 (2015).

[38] Adams, D. S., Masi, A. & Levin, M. H+ pump-dependent changes in membrane voltage are an early mechanism necessary and sufficient to induce Xenopus tail regeneration. Development 134, 1323-1335, doi:10.1242/dev.02812 (2007).

[39] Hu, Y. et al. Lysosomal pH Plays a Key Role in Regulation of mTOR Activity in Osteoclasts. J Cell Biochem 117, 413-425, doi:10.1002/jcb.25287 (2016).

[40] Hyde, D. R., Godwin, A. R. & Thummel, R. In vivo electroporation of morpholinos into the regenerating adult zebrafish tail fin. J Vis Exp, doi:10.3791/3632 (2012).

[41] Hozumi, S. et al. DEAD-Box Protein Ddx46 Is Required for the Development of the Digestive Organs and Brain in Zebrafish. PLoS One 7, e33675, doi:PONE-D-11-19641 [pii]10.1371/journal.pone.0033675 (2012).

[42] Hirose, K., Shimoda, N. & Kikuchi, Y. Transient reduction of 5-methylcytosine and 5-hydroxymethylcytosine is associated with active DNA demethylation during

regeneration of zebrafish fin. Epigenetics 8, 899-906, doi:10.4161/epi.25653 (2013).

[43] Chandra, P., Rajmani, R. S., Verma, G., Bhavesh, N. S. & Kumar, D. Targeting Drug-Sensitive and -Resistant Strains of Mycobacterium tuberculosis by Inhibition of Src Family Kinases Lowers Disease Burden and Pathology. mSphere 1, doi:10.1128/mSphere.00043-15 (2016).

[44] Muto, A., Calof, A. L., Lander, A. D. & Schilling, T. F. Multifactorial origins of heart and gut defects in nipbl-deficient zebrafish, a model of Cornelia de Lange Syndrome. PLoS Biol 9, e1001181, doi:10.1371/journal.pbio.1001181 (2011).

#### **FIGURES**



# Figure 1. Activation of S6K was not inhibited by pharmacological inhibitors of IGF or Wnt signaling at 3 hpa.

(A) Scheme of inhibitor treatments for rapamycin (a mTORC1 inhibitor), NVP-ADW742 (an IGF-1R inhibitor), and IWP-2 (a Wnt/ $\beta$ -catenin inhibitor) from -12 to 12 hpa. (B) Bright-field images of longitudinal ray sections of wild-type (WT) stumps (0 and 1-12 hpa) and fin regenerates (36 hpa). Black and red dotted lines indicate the amputation planes (amp) and the border between epidermis and blastema, respectively. (C-F', H-K', and M-P') Longitudinal ray sections of DMSO- or inhibitors-treated WT fin stumps that were immunohistochemically stained with an antibody against p-S6K (green) at 3, 6, and 12 hpa (n = 5). 4,6-diamidino-2-phenylindole dihydrochloride (DAPI) fluorescent signal (grayscale; pseudo color) indicates the presence of nuclei. Representative images used for quantification are shown in G, L, and Q along with a

highly magnified view. White dashed lines indicate the amputation planes. Scale bars: 50  $\mu$ m (C-F, H-K, and M-P) and 25  $\mu$ m (C'-F', H'-K', and M'-P'). (G, L, and Q) Quantification of the p-S6K fluorescence intensities per area that consist of the whole regenerates and 500  $\mu$ m below the amputation plane (including the intra-ray, epidermal, and wound epidermal cells) in rapamycin-, NVP-ADW742-, or IWP-2-treated fin stumps at 3 (G), 6 (L), and 12 (Q) hpa (n = 5). n.s.: not significant. \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error.



#### Figure 2. v-ATPase activity is required for the S6K activation.

(A) Experimental scheme. DMSO, ConcA, or BafA1 solution was injected into the amputated fins at 1 hpa. The red two-headed-arrow indicates LysoTracker treatment, which was applied 15 min before observation. (B-E) Longitudinal ray sections and quantification of p-S6K fluorescence intensities per area that consist of the whole regenerates and 500 µm below the amputation plane in DMSO-, ConcA-, or BafA1treated fin stumps at 3 hpa; p-S6K and nuclei were visualized by immunohistochemical staining and DAPI staining, respectively (n = 5). Representative images (B-D') used for White dashed lines indicate the amputation planes. quantification are shown in E. Scale bars: 50  $\mu$ m (B-D) and 25  $\mu$ m (B'-D'). \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error. (F) Western blotting analysis of yTubulin, S6K, and p-S6K in the DMSO-, ConcA-, or BafA1-treated fin stumps at 3 hpa (n = 6).  $\gamma$ Tubulin serves as a loading control. Numbers below each lane show the level of p-S6K in ConcA-, or BafA1-treated fin stumps relative to that in DMSO-treated fin stumps at 3 hpa normalized to loading control. (G-I') Images of bright-field and fluorescence (red) microscopy, and quantification of the LysoTracker fluorescence intensity (see Materials

and Methods) of DMSO-, ConcA-, or BafA1-treated fin stumps (n = 8). Black boxed areas in G-I are enlarged in G'-I', respectively. The LysoTracker fluorescence intensities in red boxed areas were measured (G-I'). Representative images (G'-I') used for quantification are shown in J. White dashed lines indicate the amputation planes. Scale bars: 1 mm (G-H) and 500  $\mu$ m (G'-H'). \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error.



#### Figure 3. Requirement of lysosomal acidification in the S6K activation.

(A) Experimental scheme. NH4Cl or chloroquine (CQ) was treated from -12 to 3 or 24 hpa (B-G). LysoTracker solution was injected into the amputated fins 15 min before (B-E) Longitudinal ray sections and quantification of p-S6K fixation (H-K). fluorescence intensities per area that consist of the whole regenerates and 500 µm below the amputation plane in control, NH4Cl-, or CQ-treated fin stumps at 3 hpa; p-S6K and nuclei were visualized by immunohistochemical staining and DAPI staining, respectively (n = 5). Representative images (B-D') used for quantification are shown in E. White dashed lines indicate the amputation planes. Scale bars: 50 µm (B-D) and 25 µm (B'-\*\*\*p < 0.001 by Student's t test. Error bars represent the standard error. D'). (F) Western blotting analysis of yTubulin, S6K, and p-S6K in the DMSO-, NH4Cl-, or CQtreated fin stumps at 3 hpa. yTubulin serves as a loading control. Numbers below each lane show the level of p-S6K in NH4Cl-, or CQ-treated fin stumps relative to that in DMSO-treated fin stumps at 3 hpa normalized to loading control. (G) The relative expression of growth factor-related genes in NH4Cl- or CQ-treated fin stumps by qPCR \*\*\*p < 0.001, \*\* p < 0.05 by Student's t test. Error bars represent the at 24 hpa.

standard error. (H-K) Longitudinal ray sections and quantification of p-S6K+ and LysoTracker fluorescence+ cells in area that consist of the whole regenerates and 500  $\mu$ m below the amputation plane at 3 hpa; p-S6K (green), nuclei (grayscale), and lysosomal acidification (red) were visualized by immunohistochemical staining, DAPI, and LysoTracker (Lyso.), respectively (n = 8). White boxed areas in H are enlarged in I-J', respectively. Representative images (H-J') used for quantification are shown in K. Arrowheads in I' and J' indicate LysoTracker fluorescence and p-S6K double positive cells. Scale bars: 50  $\mu$ m (H) and 25 $\mu$ m (I-J'). A pie chart shows that 55.4 % of p-S6K+ cells are the LysoTracker fluorescence positive cells (K).



Figure 4. Position-dependent lysosomal acidification during fin regeneration.

(A) Experimental scheme. Red two-headed-arrows indicate LysoTracker treatment, which was applied 15 min before observation. For cryosections, LysoTracker solution was injected into the amputated fins 15 min before fixation. (B-E") Bright-field and fluorescent images of LysoTracker-treated fins at 1, 3, 6, and 12 hpa (n = 5). Black boxed areas in B-E are enlarged in B'-E' and B"-E", respectively. The LysoTracker fluorescence intensities in red boxed areas were measured (B-E"). Representative images (B'-E") used for quantification are shown in F. White dashed lines indicate the amputation planes. Scale bars: 3 mm (B-E) and 500  $\mu$ m (B'-E' and B"-E"). (F) Quantification of Lysotracker fluorescence intensities at the proximal and distal positions at 1, 3, 6, and 12 hpa (n = 5). n.s.: not significant. \*\*\*p < 0.001, \*\* p < 0.05 by

Student's t test. Error bars represent the standard error. (G-I) Longitudinal ray sections and quantification of ratios of LysoTracker fluorescence-positive cell number/total cell number (RLTs) within 500  $\mu$ m of the amputation plane at 3 hpa (n = 5). Representative images (G and H) used for quantification are shown in I. Arrowheads indicate LysoTracker fluorescence-positive cells (red). Scale bars: 50  $\mu$ m (G and H) n.s.: not significant. \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error.





(A-E) Longitudinal ray sections (3 and 12 hpa) and quantification of p-S6K fluorescence intensities per area that consist of the whole regenerates and 500  $\mu$ m below the amputation plane (3, 6, 12, and 18 hpa) of proximal and distal positions in WT fins; p-S6K and nuclei were visualized by immunohistochemical staining and DAPI staining, respectively (n = 8). Representative images (A-D') used for quantification are shown in E. White dashed lines indicate the amputation planes. Scale bars: 50  $\mu$ m (A-D) and 25 $\mu$ m (A'-D'). \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error. (F) Western blotting analysis of  $\gamma$ Tubulin, S6K, and p-S6K in WT fin stumps at 3 and 12 hpa.  $\gamma$ Tubulin serves as a loading control. Numbers below each lane show the level of p-S6K in proximal fin stumps relative to that in distal fin stumps at 3 or 12 hpa normalized to loading control, respectively. (G-J) Longitudinal ray sections of proximal and distal fins in WT fins at 36 and 48 hpa; PCNA and nuclei were visualized by

immunohistochemical staining and DAPI staining, respectively (n = 5). Representative images (G-J) used for quantification are shown in K. White dashed lines indicate the amputation planes. Scale bars: 50  $\mu$ m (G-J). (K) Ratios of PCNA-positive cell number/total cell number (RPTs) in whole regenerates at 36 and 48 hpa (n = 5). \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error.





(A) The relative expression of *slc7a5* in proximal and distal fin regenerates at 0, 1, 3, 6, and 12 hpa by qPCR analyses. (B) Scheme of vivo-MO mediated knockdown experiments from -3 to 48 hpa. A red two-headed-arrow indicates LysoTracker treatment, which was applied 15 min before observation. Syringes indicate vivo-MO injection. (C-F) Outgrowth of fin regenerates and quantification of their length after being injected with standard vivo-MO (st-MO) or *slc7a5* vivo-MO (*slc7a5*-MO) at 48 hpa (n = 5). The boxed areas in C are enlarged in D and E, respectively. Representative images (C-E) used for quantification are shown in F. Black dashed lines indicate the amputation planes. Scale bars: 1 mm (C) and 250 µm (D and E). \*\*\*p <

0.001 by Student's t test. Error bars represent the standard error. (G-I) Longitudinal ray sections and quantification of p-S6K fluorescence intensities per area that consist of the whole regenerates and 500  $\mu$ m below the amputation plane in st-MO or *slc7a5*-MO injected fin stumps at 3 hpa; p-S6K and nuclei were visualized by immunohistochemical staining and DAPI staining, respectively (n = 8). Representative images (G-H') used for quantification are shown in I. Scale bars: 50 µm (G and H) and 25 µm (G'-H'). \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error. (J) Western blotting analysis of yTubulin, S6K, and p-S6K in st-MO or *slc7a5*-MO injected fin stumps at 3 hpa (n = 5).  $\gamma$ Tubulin serves as a loading control. Numbers below each lane show the level of p-S6K in st-MO injected fin stumps relative to that in *slc7a5*-MO injected fin stumps at 3 hpa normalized to loading control. (K) The relative expression of growth factor-related genes in st-MO- or *slc7a5*-MO-injected fins by qPCR at 24 hpa. \*\*\*p < 0.001. Error bars represent the standard error. (L-N) Images of bright-field and fluorescence microscopy, and quantification of LysoTracker fluorescence intensities in st-MO- or *slc7a5*-MO-injected fin stumps at 3 hpa (n = 5). Black boxed areas in L and M are enlarged in L' and M', respectively. The LysoTracker fluorescence intensities in red boxed areas were measured (L-M'). Representative images (L'-M') used for quantification are shown in N. Scale bars: 1 mm (L and M) and 500 µm (L' and M'). \*\*\*p < 0.001. Error bars represent the standard error.



### Figure 7. Leucine and glutamine treatment activates mTORC1 signaling via v-ATPase activity and lysosomal acidification.

(A) Experimental scheme. (B-F) Longitudinal ray sections (3 hpa) and quantification of p-S6K fluorescence intensities per area that consist of the whole regenerates and 500  $\mu$ m below the amputation plane (3, 6, and 12 hpa) of proximal and distal positions in control or LG-treated fin regenerates; p-S6K and nuclei were visualized by immunohistochemical staining and DAPI staining, respectively (n = 6).

Representative images (B-E) used for quantification are shown in F. White dashed lines indicate the amputation planes. Scale bars: 50  $\mu$ m. \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error. (G) Western blotting analysis of yTubulin, S6K, and p-S6K in proximally and distally amputated LG-treated fin stumps at 3 hpa.  $\gamma$ Tubulin serves as a loading control. Numbers below each lane show the level of p-S6K in proximally or distally amputated LG-treated fin stumps relative to that in proximally or distally amputated control fin stumps at 3 hpa normalized to loading control, respectively. (H-L) Longitudinal ray sections and RPT quantification in proximally and distally amputated control or LG-treated fin regenerates at 36 hpa; PCNA and nuclei were visualized by immunohistochemical staining and DAPI staining, respectively (n = 5). Representative images (H-K) used for quantification are shown in L. White dashed lines indicate the amputation planes. Scale bars: 50  $\mu$ m. \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error. (M) The relative expression of growth factorrelated genes in control and LG-treated fin regenerates by qPCR at 24 hpa. n.s.: not \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error. significant. (N-S) Longitudinal ray sections and quantification of p-S6K fluorescence intensities per area that consist of the whole regenerates and 500 µm below the amputation plane in control, LG-treated, LG-treated and DMSO-injected (LG + DMSO), LG-treated and ConcA-injected (LG + ConcA), or LG- and NH<sub>4</sub>Cl-treated (LG + NH<sub>4</sub>Cl) fin stumps at 3 hpa; p-S6K and nuclei were visualized by immunohistochemical staining and DAPI staining, respectively (n = 5). Representative images (N-R) used for quantification are shown in S. White dashed lines indicate the amputation planes. Scale bars: 50 µm. \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error. (T) Western blotting analysis of yTubulin, S6K, and p-S6K in control, LG-treated, LG + DMSO, LG + ConcA, or LG + NH4Cl fin stumps at 3 hpa (n=6).  $\gamma$ Tubulin serves as a loading control. Numbers below each lane show the level of p-S6K in LG-treated, LG + DMSO, LG + ConcA, or LG + NH4Cl fin stumps relative to that in control fin stumps at 3 hpa normalized to loading control.

### Supplementary figures



# Figure S1. Western blot analysis of rapamycin-, NVP-ADW742-, or IWP-2-treated fin stumps.

Western blot analysis of  $\gamma$ Tubulin, S6K, and p-S6K in rapamycin-, NVP-ADW742-, or IWP-2-treated fin stumps at 3 and 12 hpa (n = 5).  $\gamma$ Tubulin serves as a loading control. Numbers below each lane show the level of p-S6K in rapamycin-, NVP-ADW742-, or IWP-2-treated fin stumps relative to that in DMSO-treated fin stumps at 3 or 12 hpa normalized to loading control, respectively.



#### Figure S2. Lysosomal acidification during fin regeneration.

(A) Experimental scheme. Red two-headed-arrows indicate LysoTracker treatment, which was applied 15 min before observation. (B-F') Images of bright-field and fluorescence microscopy, and quantification of LysoTracker fluorescence intensities at 0, 3, 6, 12, and 24 hpa (n = 5). Black boxed areas in B-F are enlarged in B'-F', respectively. The LysoTracker fluorescence intensities in red boxed areas were measured (B-F'). Representative images (B'-F') used for quantification are shown in G. White dashed lines indicate the amputation planes. Scale bars: 1 mm (B-F) and 500  $\mu$ m (B'-F'). n.s.: not significant. \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error.



#### Figure S3. Lysosomal acidification in NH4Cl- and CQ-treated fins.

(A) Experimental scheme. A red two-headed-arrows indicates LysoTracker treatment, which was applied 15 min before observation. (B-E) Images of bright-field and fluorescence microscopy, and quantification of LysoTracker fluorescence intensities in control, NH<sub>4</sub>Cl-, or CQ-treated fins at 3 hpa (n = 8). Black boxed areas in B-D are enlarged in B'-D', respectively. The LysoTracker fluorescence intensities in red boxed areas were measured (B-D'). Representative images (B'-D') used for quantification are shown in E. White dashed lines indicate the amputation planes. Scale bars: 1 mm (B-D) and 500 µm (B'-D'). \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error.





(A) Experimental scheme. NH<sub>4</sub>Cl or chloroquine (CQ) was treated from -12 to 3 or 24 hpa. (B-G) Longitudinal ray sections and quantification of TUNEL positive cells/total cell number per area that consists of the whole regenerates and 500  $\mu$ m below the amputation plane in control, NH<sub>4</sub>Cl-, or CQ-treated fin stumps at 3 and 24 hpa; apoptotic cells and nuclei were visualized by immunohistochemical staining and DAPI staining, respectively (n = 5). Representative images (B-G) used for quantification are shown in H. White dashed lines indicate the amputation planes. Scale bars: 50  $\mu$ m (B-G). n.s.: not significant. Error bars represent the standard error.





The relative expression of the four *LATs* genes (*slc7a8a*, *slc7a8b*, *slc43a1a*, *and slc43a1b*) at 0, 3, 6, and 12 hpa by qPCR. Error bars represent the standard error.



#### Figure S6. slc7a5 pre-mRNA splicing was blocked by vivo-MO.

(A) Scheme of the *slc7a5* pre-mRNA regions analyzed for splicing (boxed, exons; lines, introns; arrows, primers). (B) Spliced PCR products of *slc7a5*, obtained by qPCR, were significantly reduced in *slc7a5*-MO-injected fins when compared to in st-MO-injected fins by qPCR. \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error.



#### Figure S7. S6K activation and lysosomal acidification are inhibited by JPH203.

(A) Scheme of JPH203 (Slc7a5-specific inhibitor) treatment from -12 to 3 or 48 hpa. A red two-headed-arrow indicates LysoTracker treatment, which was applied 15 min before observation. (B-D) Outgrowth of fin regenerates and quantification of their length in control or JPH203-treated fin regenerates at 48 hpa (n = 5). Representative images (B and C) used for quantification are shown in D. Black dashed lines indicate Scale bars: 250 µm. \*\*\*p < 0.001 by Student's t test. Error the amputation planes. bars represent the standard error. (E-G) Longitudinal ray sections and quantification of p-S6K fluorescence intensities per area that consists of the whole regenerates and 500 µm below the amputation plane in DMSO- or JPH203-treated fin regenerates at 3 hpa; p-S6K and nuclei were visualized by immunohistochemical staining and DAPI staining, respectively (n = 5). Representative images (E-F') used for quantification are shown in White dashed lines indicate the amputation planes. Scale bars: 50 µm (E and F) G. \*\*\*p < 0.001 by Student's t test. Error bars represent the and 25  $\mu$ m (E' and F'). standard error. (H) Western blot analysis of  $\gamma$ Tubulin, S6K, and p-S6K in the DMSOor JPH203-treated fin stumps (n = 6).  $\gamma$ Tubulin serves as a loading control. Numbers

below each lane show the level of p-S6K in JPH203-treated fin stumps relative to that in DMSO-treated fin stumps at 3 hpa normalized to loading control. (I-K) Images of bright-field and fluorescence microscopy, and quantification of LysoTracker fluorescence intensities in DMSO- or JPH203-treated fins at 3 hpa (n = 8). Black boxed areas in I and J are enlarged in I' and J', respectively. The LysoTracker fluorescence intensities in red boxed areas were measured (I-J'). Representative images (I'-J') used for quantification are shown in K. White dashed lines indicate the amputation planes. Scale bars: 1 mm (I and J) and 500  $\mu$ m (I' and J'). \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error.



#### Figure S8. Leucine or glutamine treatment has no effect on S6K activation.

(A) Experimental scheme of leucine or glutamine treatment from -12 to 3 hpa. (B-E) Longitudinal ray sections and quantification of p-S6K fluorescence intensities per area that consists of the whole regenerates and 500  $\mu$ m below the amputation plane in control, leucine-, or glutamine-treated fin regenerates at 3 hpa; p-S6K and nuclei were visualized by immunohistochemical staining and DAPI staining, respectively (n = 5). Representative images (B-D') used for quantification are shown in E. White dashed lines indicate the amputation planes. Scale bars: 50  $\mu$ m. n.s.: not significant. Error bars represent the standard error.





(A) Experimental scheme of leucine and/or glutamine treatment from -12 to 3 hpa. A red two-headed-arrow indicates LysoTracker treatment, which was applied 15 min before observation. (B-P) Images of bright-field and fluorescence microscopy, and quantification of LysoTracker fluorescence intensities in fin stumps at 3 hpa (n = 6). Black boxed areas in B-E, G-J, and L-O are enlarged in B'-E', G'-J', and L'-O', respectively. The LysoTracker fluorescence intensities in red boxed area were measured (B-E', G-J', and L-O'). Representative images (B-E', G-J', and L-O') used for quantification are shown in F, K, and P. White dashed lines indicate the amputation planes. Scale bars: 1 mm (B-E, G-J, and L-O) and 500  $\mu$ m (B'-E', G'-J', and L'-O'). \*\*\*p < 0.001 by Student's t test. Error bars represent the standard error.



# Figure S10. Upregulation of lysosome acidification by LG treatment is blocked by *Slc7a5* knockdown.

(A) Experimental scheme of LG treatment from -12 to 3 hpa. A red two-headedarrow indicates LysoTracker treatment, which was applied 15 min before observation. A syringe indicates vivo-MO injection at -3 hpa. (B-D') Images of bright-field and fluorescence microscopy, and quantification of LysoTracker fluorescence intensities in st-MO-, LG-treated and st-MO-injected (LG + st-MO), or LG-treated and *slc7a5*-MOinjected (LG + *slc7a5*-MO) fin stumps at 3 hpa (n = 6). Black boxed areas in B-D are enlarged in B'-D', respectively. The LysoTracker fluorescence intensities in red boxed areas were measured (B-D'). Representative images (B'-D') used for quantification are shown in E. Scale bars: 1 mm (B-D) and 500  $\mu$ m (B'-D'). \*\*\**p* < 0.001. Error bars represent the standard error.



#### Figure S11. A proposed model of position-dependent fin regeneration in zebrafish.

For discussion, see text. Leucine and glutamine are proximally enriched in unamputated fins. The position-dependency of slc7a5 expression, lysosomal acidification, and mTORC1 activity is found in this study (marked by red boxes).

### Table S1

	Primer sequences 5' to 3'			
Gene name	Forward primer	Reverse primer	Ref.	
qRT-PCR				
wnt10a	ATTCACTCCAGGATGAGACTTCATA	GTTTCTGTTGTGGGGCTTTGATTAG	1	
igf2b	GCAGGTCATTCCAGTGATGC	TCTGAGCAGCCTTTCTTTGC	2	
aldh1a2	GCTTACCTTGCTACCCTGGAGTC	CAATGGGCTCATGTCTGGTGAG	This study	
fgf20a	GGACCACAGCAGATTTGGTATATTGG	CAGCTTTTCAGATCCGTACAGTTCGC	This study	
slc7a5	GGAGATCGGCAAAGGTGATAC	GCTCAATCATCTCCTCTGTGAC	This study	
slc7a8a	GCAGGGTTTCTGCGATTATGG	CAAGTCAGCAGCAACAAGCAG	This study	
slc7a8b	CAGCAAGAAGAGCAGGAATGG	GTTTGGAAGTCTCTCTGTGCC	This study	
slc43a1a	CGTAACGTCACGGTTAGCACTT	CTTCACCAGTAGCATTCACTGTC	This study	
slc43a1b	GGCAGCATCAGGAGAAGAAGTG	CGAACACAGCAGGTTCTCCAAC	This study	
rpl13a	TCTGGAGGACTGTAAGAGGTATGC	AGACGCACAATCTTGAGAGCAG	3	
checking morpholino efficacy				
slc7a5	TGAAACTGTGGATCGAGCTG	AGGCATCTTGAACCCTTGTG	4	

### References

[1] Bouzaffour, M., Dufourcq, P., Lecaudey, V., Haas, P. & Vriz, S. Fgf and Sdf-1 pathways interact during zebrafish fin regeneration. PLoS One 4, e5824, doi:10.1371/journal.pone.0005824 (2009).

[2] Chablais, F. & Jazwinska, A. IGF signaling between blastema and wound epidermis is required for fin regeneration. Development 137, 871-879, doi:10.1242/dev.043885 (2010).

[3] Hirose, K., Shimoda, N. & Kikuchi, Y. Transient reduction of 5-methylcytosine and 5-hydroxymethylcytosine is associated with active DNA demethylation during regeneration of zebrafish fin. Epigenetics 8, 899-906, doi:10.4161/epi.25653 (2013).

[4] Chung, J. et al. The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability. Sci Signal 8, ra34, doi:10.1126/scisignal.aaa5903 (2015).

Chapter 3. General discussion

#### **General discussion**

Positional memory is of one the unsolved issues in the regeneration field. How is regeneration regulated such that the organ achieves its original formation? It is an important working as well as initiation of regeneration especially in vivo regeneration therapy. By resolving this, I believe that this can possibly be applied directly in the therapy of function defective organs in the future.

In this research, we applied approaches to elucidate its mechanism using a simplified experimental system on zebrafish fins. Furthermore, we clarified new factors through screening experiments using various inhibitors and drugs, revealing a part of the mechanism in positional memory. In this study, it was revealed that amino acids, which is important in our daily life activity, have a critical function in the process of tail fin regeneration. Previously, it was reported that the mTORC1 pathway influences various factors involved in regeneration from the early stage during zebrafish tail regeneration process. However, the activation of the mTORC1 pathway could be confirmed immediately after amputation when the induction of growth factor had not started, so other functions of mTORC1 pathway could be expected. What is upstream of the mTORC1 pathway in the early stage of fin regeneration? According to the results of this study, it was revealed that incorporation of amino acids induced the activation of the mTORC1 pathway immediately just after fin amputation.

Further research revealed that the overtaking of amino acids, particularly leucine which is one of the branched amino acids, had been greatly induced in the early stage of regeneration with the mediation of the transporter. This branched chain amino acid had been known as an important factor in our life [1]. Compared with other amino acids, leucine is rapidly incorporated into the body and is known to greatly affect muscle repair because the it directly regulates the expression of eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) through the mTOR pathway. In recent years, many athletes are beginning to incorporate it in muscle enhancing supplement foods [2]. This means that taking in leucine, along with other amino acids, is an easier way to improve the condition in our body than other therapies. These amino acids have already been reported to affect differentiation not only in the muscle cell [3], but also in the pancreatic cell [4], neuronal cell [5], and so on [6][7]. However, the mechanism of the amino acid effect has been unknown especially in developmental stage and cell differentiation [8][9].

In addition, fin regeneration with leucine and glutamine amino acid treatment was attempted, but no fin elongation was observed. It was because cell death occurred during the fin regeneration with long time amino acid treatment. In general, the amino acid, especially leucine, enters the metabolic pathway with the branched transferase and changes various important molecules [10]. One of these processes is the N-acetyl-1leucine induced cell death via the p53 pathway, which occurs not only in cancer cells but also in some somite cells [11]. In fact, it had been confirmed that the gene expression of the branching type amino acid modification enzyme, BCAT, rapidly upregulated the expression immediately after fin amputation during regeneration. These results implied that the metabolic pathways, N-acetyl-1-leucine related pathway, were activated, and the cell death signaling pathway had been activated in same time. Additionally, it had been reported that the mTORC1 pathway was activated even in cell death induced cells and these reports suggest that the next step is to induce fin regeneration with inhibition of the cell death. If the cell death pathway will be inhibited in fin regeneration with leucine and glutamine treatment, what will happen during fin regeneration? Can we observe fin growth which implies regeneration activation? There is a way to inhibit the cell death pathway in zebrafish model system by using the inhibitor of some caspases or the mutant in p53. I believe it is possible to activate the regeneration, but the experiment has not been done yet.

Recently, regenerative therapy are hot topics especially by using and *in vitro* system. There are different systems in *in vitro* therapy, ES cells [12], iPS cells [13], and other cell culture system [14][15][16]. If these systems can be applied to our therapy, many people who have diseases and defects in the organ or tissue will benefit from these. However, these systems still have risks as much as benefits. The most important problem is the high risk of carcinoma cells to develop and they have to be clear for our clinical trial. Many researchers are trying to find a safer way to apply this therapy. Now, we know in vivo regenerative therapy can possibly make therapy application safer. If we can directly induce organ or tissue regeneration in our body, will these therapies be rejected by the body or will carcinoma develop? Of course, nobody can answer these questions, but we know the risk is lower in *in vivo* than *in vitro* therapy because we do not need to transplant the cells from outside and use the cells derived from others. Additionally, applying the treatment inside the body might be less expensive and efficient. I believe that in vivo therapy will take the place of the iPS cell or regeneration therapy in the near future. If we can directly induce the whole organ or tissue in the body and use an easy treatment, like a 2 type amino acid treatment, many people can be treated more effectively.

### References

- Bajada, S., Mazakova, I., Richardson, J. B. & Ashammakhi, N. Updates on stem cells and their applications in regenerative medicine. *Journal of Tissue Engineering and Regenerative Medicine* 2, 169-183, doi:10.1002/term.83 (2008).
- 2 Brosnan, J. T. & Brosnan, M. E. Branched-chain amino acids: Enzyme and substrate regulation. *Journal of Nutrition* **136**, 207S-211S (2006).
- 3 Cossu, G. *et al.* Lancet Commission: Stem cells and regenerative medicine. *Lancet* **391**, 883-910, doi:10.1016/s0140-6736(17)31366-1 (2018).
- Csobonyeiova, M., Polak, S., Zamborsky, R. & Danisovic, L. iPS cell technologies and their prospect for bone regeneration and disease modeling: A mini review. *Journal of Advanced Research* 8, 321-327, doi:10.1016/j.jare.2017.02.004 (2017).
- 5 Garcia-Espinosa, M. A., Wallin, R., Hutson, S. M. & Sweatt, A. J. Widespread neuronal expression of branched-chain aminotransferase in the CNS: implications for leucine/glutamate metabolism and for signaling by amino acids. *Journal of Neurochemistry* 100, 1458-1468, doi:10.1111/j.1471-4159.2006.04332.x (2007).
- Kimbrel, E. A. & Lanza, R. Pluripotent stem cells: the last 10 years.
   *Regenerative Medicine* 11, 831-847, doi:10.2217/rme-2016-0117 (2016).
- Mansfeld, J. *et al.* Branched-chain amino acid catabolism is a conserved regulator of physiological ageing. *Nature Communications* 6, doi:10.1038/ncomms10043 (2015).
- Mao, A. S. & Mooney, D. J. Regenerative medicine: Current therapies and future directions. *Proceedings of the National Academy of Sciences of the United States of America* 112, 14452-14459, doi:10.1073/pnas.1508520112 (2015).
- 9 Nyman, S., Sopanen, T. & Mikola, J. REGULATION OF DEVELOPMENT OF LEUCINE UPTAKE ACTIVITY BY GLUTAMINE IN THE SCUTELLUM OF GERMINATING BARLEY-GRAIN. *Plant Physiology* 73, 135-141, doi:10.1104/pp.73.1.135 (1983).
- 10 Pedroso, J. A. B., Zampieri, T. T. & Donato, J. Reviewing the Effects of l-Leucine Supplementation in the Regulation of Food Intake, Energy Balance, and Glucose Homeostasis. *Nutrients* 7, 3914-3937, doi:10.3390/nu7053914 (2015).
- 11 Pereira, M. G. et al. Leucine Supplementation Improves Skeletal Muscle

Regeneration after Cryolesion in Rats. *Plos One* **9**, doi:10.1371/journal.pone.0085283 (2014).

- 12 Rachdi, L., Aiello, V., Duvillie, B. & Scharfmann, R. L-Leucine Alters Pancreatic beta-Cell Differentiation and Function via the mTor Signaling Pathway. *Diabetes* 61, 409-417, doi:10.2337/db11-0765 (2012).
- 13 She, P. X. *et al.* Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. *American Journal of Physiology-Endocrinology and Metabolism* 293, E1552-E1563, doi:10.1152/ajpendo.00134.2007 (2007).
- 14 Suryawan, A., Orellana, R. A., Fiorotto, M. L. & Davis, T. A. TRIENNIAL GROWTH SYMPOSIUM: Leucine acts as a nutrient signal to stimulate protein synthesis in neonatal pigs. *Journal of Animal Science* 89, 2004-2016, doi:10.2527/jas.2010-3400 (2011).
- Tabar, V. & Studer, L. Pluripotent stem cells in regenerative medicine: challenges and recent progress. *Nature Reviews Genetics* 15, 82-92, doi:10.1038/nrg3563 (2014).
- 16 Twigger, A. J. & Scheel, C. H. Advances in stem cells and regenerative medicine: single-cell dynamics, new models and translational perspectives. *Development* 144, 3007-3011, doi:10.1242/dev.153569 (2017).

### Acknowledgement

I would like to gratefully hank my supervisor Prof. Yutaka Kikuchi (Hiroshima University) for his critical instruction, encouragement and patience this thesis. I also thank Akihiko Muto, and Shunya Hozumi (Hiroshima University) for their technical advise, valuable discussion, and helpful instruction; Dr Atushi Szuki, all member of Atushi Suzuki laboratory for helpful discussion and critical comments; and the member of our laboratory for supporting the experiments.